Loading
A phase 2 trial of Evorpacept, Pembrolizumab in head and neck squamous cell carcinoma, run by ALX Oncology Inc., active and no longer recruiting.
Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03) is a phase 2 interventional study registered as NCT04675294 by ALX Oncology Inc., with 189 participants enrolled, started 2021-04-02 and due to reach its primary completion in 2025-03-03. Interventions recorded: evorpacept, pembrolizumab. Conditions listed: Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares ALX Oncology, Evorpacept, CD47 and SIRP-alpha blockade, Head and neck squamous cell carcinoma.
Shares ALX Oncology, Evorpacept, CD47 and SIRP-alpha blockade.
Shares ALX Oncology, Evorpacept, CD47 and SIRP-alpha blockade.
Shares ALX Oncology, Evorpacept.
Shares ALX Oncology, CD47 and SIRP-alpha blockade.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/